tbuckley/cabot-search huggingface dataset:
PTU-157 Reviewing The Standardised Approach – An Audit of 250 Barrett’s Surveillance Cases
Authors: R Das, A Mandal, D Leonard, S Nawaz
Journal: Gut (2016)

<h3>Introduction</h3> Barrett’s oesophagus (BO) confers a relative risk of 11.3 over that of the general population for the development of oesophageal adenocarcinoma.(Hyid 2011) The endoscopic surveillance of BO remains the only modality for the detection of emergent dysplasia, which has been established as a premalignant development.(Flejou 2005) The 2013 BSG Guideline on BO explicitly suggests the use of a ‘minimum dataset’ in order to standardise BO reporting and for the audit of this practice in order to ensure high quality BO management.(Fitzgerald et al. 2013) <h3>Methods</h3> The advised minimum dataset includes the standardised ‘Prague classification’ and hiatus hernia reporting. We report the audit of standardised reporting in 250 patients – a volume that represents roughly forty percent of the annual Barrett’s surveillance load in between two large District General Hospitals in Lincolnshire(UK). <h3>Results</h3> Adherence to the ‘Prague Classification’ was demonstrated in 56% of reports (141 of 250). The Gastro-oesophageal-junction was only documented as being noted in 44% (109 of 250), with length of hiatus hernias being documented in 61% (105 of 173). Nurse endoscopists and doctors utilised the Prague classification equally – 48% and 52% respectively. Nurse endoscopists reported hiatus hernia length in only 38% of cases, with doctor (any grade) reporting at 62%. Interestingly overall only 32% of reports made any mention of proton pump inhibitor (PPI) use or advised of PPI initiation. Of the total (n = 250) 7 cases of dysplasia and 4 cases of adenocarcinoma were detected. The single detected high-grade dysplasia was referred appropriately for UGI multidisciplinary team input. Two cases of indefinite dysplasia were noted, and repeat endoscopy planned within a 6 month period. The overall finding of 11 cases (4.4%) of dysplasia or malignancy was in keeping with expected detection rates as reported by recent meta-analyses.(Qiao 2015) <h3>Conclusion</h3> While dysplasia and adenocarcinoma detection rates are within acceptable ranges, improved adherence to the ‘minimum dataset’ is needed. We have recommended serial clinical update sessions for endoscopists and planned further re-audit. <h3>References</h3> 1 Pietro M, Ragunath K, <i>et al</i>. British society of gastroenterology guidelines on the diagnosis and management of Barrett’s Oesophagus. <i>Gut</i>. 2013;<b>10</b>:1136–40. 2 Flejou JF. Barrett’s oesophagus: from metaplasia to dysplasia and cancer. <i>Gut</i>. 2005;<b>54</b>:1–12. 3 Hvid-Jensen F, Pedersen L, Drewes A, <i>et al</i>. Incidence of adenocarcinoma among patients with Barrett’s oesophagus. <i>N Engl J Medi</i>. 2011. <b>365</b>: 1375–83. 4 Qiao Y, Hyder A, <i>et al</i>. Surveillance in patients with Barrett’s Oesophagus for early detection of Esophageal Adenocarcinoma: A systematic review. <i>Gastroenterology</i>. 2015. <b>131</b>:1038–1040. <h3>Disclosure of Interest</h3> None Declared
AB0504 HTR2A Polymorphisms Influence in Systemic Lupus Erythematous Clinical, Immunological Manifestation and Damage Accrual
Authors: R. Faria, R.R. Dias, R. Ferreira, P.G. Pereira, I. Inácio, B.G. Leal, A.I. Tavares, A. Bettencourt, C. Carvalho, I. Almeida, A. Marinho, B. Martins da Silva, C. Vasconcelos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Serotonin receptor 1A and 2A genes polymorphisms (HTR1A and HTR2A) have been associated to increased risk of depression and suicide. Hypomethylated HTR1A has been associated to Systemic Lupus Erythematosus (SLE) patients manifestations. Preliminary results in our cohort showed an association between HTR2A polymorphisms and SLE manifestations development risk and depression risk in SLE patients. <h3>Objectives</h3> To investigate the association of 5-HTR2A polymorphisms (rs6314, rs6313) and clinical organ involvement, specific antibodies expression and damage accrual and time to damage accrual in SLE patients. <h3>Methods</h3> 75 SLE patients were evaluated for 5-HTR2A polymorphisms rs6314 and rs6313, by a Taqman assay and PCR-RFLP methodology, respectively. SLE diagnosis was based in ACR 1999 criteria, the organic involvement and specific antibodies were reviewed in the charts (Cumulative SLE manifestations for genetic studies) and damage was assessed by SDI (Systemic Lupus International Collaborating Clinics - Damage Index). Statistical analysis was made with SPSS 22.0. <h3>Results</h3> 75 SLE patients (70 female) with a mean age of diagnosis of 29.55 years old (SD 12.0) and mean follow-up time of 17,39 years (SD 7,70). Mucocutaneous involvement occurred in 88%, articular 85,3%, renal 46,7%, 30,7% neuropsychiatric. 38 patients (50,7%) had organ damage acrrual with a mean time to first damage accrual of 3,75 years (SD 6,88). 7 (9,3%) accrued renal damage and 15 (20%) neuropsychiatric. Polymorphism distribution was rs6313 (CC 22,7%, CT 54,7% e TT 14,7%) and rs 6314 (CC 86,7%, CT 13,3%). No association was found between these polymorphisms and any clinical involvement, cytopenias, antibodies, damage accrual or time to damage. Neuropsychiatric damage accrual was earlier in patients carrying CC rs6314. <h3>Conclusions</h3> Contradictory results are a very common phenomena in studies of complex diseases mainly due to the interaction fo several genes. Although poorly studied the serotonin receptor and transporter genes have been linked to SLE development and depression in SLE patients. In our study, there was no relation between any clinical or serological manifestations and the rs6313 and rs6314 HTR2A polymorphism but the earlier neuropsychiatric damage accrual opens a window of doubt of what might be the role of serotonin in SLE heterogeneity. <h3>Disclosure of Interest</h3> None declared
New LMO2 Translocations in T-Cell Acute Lymphoblastic Leukemia, Involving STAG2 at Xq25 and MBNL1 at 3q25: A Positive Change?.
Authors: Suning Chen, Stefan Nagel, Bjoern Schneider, Maren Kaufmann, Ursula R. Kees, Hans G. Drexler, Roderick A.F. MacLeod
Journal: Blood (2009)
Association of Bystander Cardiopulmonary Resuscitation and Survival According to Ambulance Response Times After Out-of-Hospital Cardiac Arrest
Authors: Shahzleen Rajan, Mads Wissenberg, Fredrik Folke, Steen Møller Hansen, Thomas A. Gerds, Kristian Kragholm, Carolina Malta Hansen, Lena Karlsson, Freddy K. Lippert, Lars Køber, Gunnar H. Gislason, Christian Torp-Pedersen
Journal: Circulation (2016)

Bystander-initiated cardiopulmonary resuscitation (CPR) increases patient survival after out-of-hospital cardiac arrest, but it is unknown to what degree bystander CPR remains positively associated with survival with increasing time to potential defibrillation. The main objective was to examine the association of bystander CPR with survival as time to advanced treatment increases.We studied 7623 out-of-hospital cardiac arrest patients between 2005 and 2011, identified through the nationwide Danish Cardiac Arrest Registry. Multiple logistic regression analysis was used to examine the association between time from 911 call to emergency medical service arrival (response time) and survival according to whether bystander CPR was provided (yes or no). Reported are 30-day survival chances with 95% bootstrap confidence intervals.With increasing response times, adjusted 30-day survival chances decreased for both patients with bystander CPR and those without. However, the contrast between the survival chances of patients with versus without bystander CPR increased over time: within 5 minutes, 30-day survival was 14.5% (95% confidence interval [CI]: 12.8-16.4) versus 6.3% (95% CI: 5.1-7.6), corresponding to 2.3 times higher chances of survival associated with bystander CPR; within 10 minutes, 30-day survival chances were 6.7% (95% CI: 5.4-8.1) versus 2.2% (95% CI: 1.5-3.1), corresponding to 3.0 times higher chances of 30-day survival associated with bystander CPR. The contrast in 30-day survival became statistically insignificant when response time was >13 minutes (bystander CPR vs no bystander CPR: 3.7% [95% CI: 2.2-5.4] vs 1.5% [95% CI: 0.6-2.7]), but 30-day survival was still 2.5 times higher associated with bystander CPR. Based on the model and Danish out-of-hospital cardiac arrest statistics, an additional 233 patients could potentially be saved annually if response time was reduced from 10 to 5 minutes and 119 patients if response time was reduced from 7 (the median response time in this study) to 5 minutes.The absolute survival associated with bystander CPR declined rapidly with time. Yet bystander CPR while waiting for an ambulance was associated with a more than doubling of 30-day survival even in case of long ambulance response time. Decreasing ambulance response time by even a few minutes could potentially lead to many additional lives saved every year.
In Vitro Characterization, Pharmacokinetics and Reversal of Supratherapeutic Doses of Dabigatran-Induced Bleeding in Rats by a Specific Antibody Fragment Antidote to Dabigatran
Authors: Joanne van Ryn, Tobias Litzenburger, Guanfa Gan, Kelly Coble, Johanna Schurer
Journal: Blood (2012)
Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience
Authors: Roberto Latagliata, Maria Antonietta Aloe Spiriti, Luca Maurillo, Carolina Nobile, Anna Lina Piccioni, Marianna Criscuolo, Virginia Naso, Antonio Spadea, Pasquale Niscola, Caterina Tatarelli, Benedetta Neri, Nicoletta Villivà, Federico Vozella, Mariella D'Andrea, Roberta Battistini, Susanna Fenu, Massimo Breccia, Stefano Mancini, Maria Teresa Voso, Francesco Buccisano
Journal: Blood (2012)
SAT0380 Nsaids Modify The Effect of Tumor Necrosis Factor Inhibitors on New Bone Formation in Ankylosing Spondylitis
Authors: L. Gensler, J.D. Reveille, M.M. Ward, M.A. Brown, M. Rahbar, M. Lee, M.H. Weisman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Radiographic damage in Ankylosing Spondylitis (AS) is largely defined by new bone formation. The beneficial effects of pharmacologic therapy on osteoproliferation have been difficult to prove. <h3>Objectives</h3> The objective of this study was to examine the relationship of NSAIDs and Tumor Necrosis Factor inhibitors (TNFi) on New bone formation in AS. <h3>Methods</h3> 511 AS patients meeting the modified New York criteria with at least 2 years of radiographic follow-up were included in this prospective longitudinal study. Progression was defined as an increase at any vertebral corner from 0/1 to 2 or 0/1 to 3 at any interval between radiographs to reflect syndesmophyte development. We grouped patients according to the interval between baseline and the last visit, and used progression as a dichotomized outcome in a mixed effect logistic regression model. Patients taking NSAIDs for more than 50% of the time between visits were considered high NSAID users for that visit. TNFi use was assessed at each visit and adjusted for baseline use and total duration. <h3>Results</h3> In our multivariable models after adjusting for significant covariates, we found that TNFi use was associated with less new bone formation in AS with the strongest association in patients who had 2.1–3.5 years of follow-up (OR=0.27; 95% CI 0.08–0.94; p=0.04) [Table 1]. Though not statistically significant, in patients who were followed up for 3.6 years or longer, the odds of progression for the TNFi user group was 41% (3.6–5.9 year group) and 14% (6+ year group) lower than in non-users (OR=0.59, OR=0.86). We found a significant interaction (p=0.01) between NSAID use and TNFi in relation to radiographic progression. Those patients exposed to both TNFi and with high NSAID use had an OR for progression of 0.31, 95% CI 0.13–0.75, compared to those not on high dose NSAIDs (OR=1.23, 95% CI 0.41–3.66). <h3>Conclusions</h3> TNFi are associated with less new bone formation in AS, and this appears to be modified by the use of NSAIDs. <h3>Disclosure of Interest</h3> L. Gensler Consultant for: AbbVie, Amgen, Janssen, Novartis, UCB, J. Reveille: None declared, M. Ward: None declared, M. Brown Grant/research support from: Janssen, Abbvie, UCB, Leo Pharma, Complete Genomics, Consultant for: Abbvie, UCB, Janssen, Pfizer, Speakers bureau: Abbvie, UCB, Pfizer, UCB, M. Rahbar: None declared, M. Lee: None declared, M. Weisman Grant/research support from: UCB, Human Genome Sciences, Sanofi, Eli Lilly and Co, Genentech, Inc., Santarus Inc., EMD Serono, ChemoCentryx, GSK, Immunomedics Inc., Consultant for: Boehringer Ingelheim/Proskauer, Ardea Biosciences, Epirus Biopharmaceuticals, Acerta Pharma
Bone Involvement in Multiple Myeloma Patients Carrying the T (4;14) Chromosomal Translocation.
Authors: Patrizia Tosi, Carolina Terragna, Testoni Nicoletta, Elena Zamagni, Matteo Renzulli, Paola Tacchetti, Elena Montanari, Giulia Perrone, Michela Ceccolini, Annamaria Brioli, Michele Baccarani, Michele Cavo
Journal: Blood (2006)
THU0229 Is There A Difference in The Presentation of Diffuse and Limited Subtype in Childhood? Results from The Juvenile Scleroderma Inception Cohort
Authors: I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, M.T. Terreri, V. Stanevicha, M.M. Katsikas, E. Alexeeva, F. Sztajnbok, R. Cimaz, M. Kostik, W.A. Sifuentes-Giraldo, T. Lehman, D. Nemcova, M. Moll, M.J. Santos, T. Avcin, C. Battagliotti, J. Brunner, S. Nielsen, T. Kallinich, K. Minden, M. Janarthanan, L. Harel, Y. Uziel, D. Eleftheriou, K.S. Torok, N. Helmus
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Several adult publications looked at the differences between limited (ljSSc) and diffuse subtype (djSSc). There is rarity of data regarding this topic in pediatric jSSc. The juvenile scleroderma inception cohort is a prospective standardized register for patients with jSSc. <h3>Objectives</h3> comparison of patients characteristic at the time of inclusion with ljSSc and djSSc <h3>Methods</h3> We compered the demographics and clinical characteristics of the ljSSc and djSSc. <h3>Results</h3> Up till now 74 patients were enrolled, 54 (76%) with djSSc and 18 with ljSSc (24%). 9% in djSSc and 25% in ljSSc showed overlap features. Disease duration at time of inclusion in the cohort was 3.7 years in the djSSc and 3.3 years in ljSSc. 82% in the djSSc and 78% in the ljSSc group were female. The mean age of the onset of Raynaud symptomatic was 9.0 years in the jdSSc and 9.9 years in ljSSc group and onset of the non-Raynaud symptomatic with 9.4 in djSSc and 10.6 ljSSc. At the time of inclusion the mean modified Rodnan Skin Score was 18.5 in the djSSc and 8,4 in ljSSc (p=0.0001). Anti-Scl 70 positivity was found in 31.5% of djSSc and 30.8% in ljSSc. Only 2 patient in the djSSc group and one in the ljSSc group was anticentromere positive. Capillary changes occurred in 60.7% in the djSSc and 50% in ljSSc, but 58.2% in djSSc and only 23.5% in ljSSc had already history of ulcerations (p=0.013) and 21.8% had active ulceration in the djSSc and 5.9% in the ljSSc. 33.3% of djSSc and 72.7% of ljSSc had cardiac involvement (p=0.027). pulmonary hypertension occurred in 57.1% djSSc and 18.2% in ljSSc. 63% in djSSc and 27.3% in ljSSc group had signs of interstitial lung disease on imaging (p=0.046). Renal involvement occurred in 7.1% djSSc and 5.6% in ljSSc. 39.3% of djSSc and 22.2% of ljSSc had gastrointestinal involvement. 56.4% in djSSc and 83.35 in ljSSc had musculoskeletal involvement (p=0.04). <h3>Conclusions</h3> Patients with djSSc have younger age at onset, have more often capillary changes and active ulcerations, pulmonary hypertension and less gastorintestinal and joint involvement and more disease damage. The characteristics of the pediatric subtypes differs from adults with SSc, especially the high proportion of patients with diffuse subtype. <h3>Disclosure of Interest</h3> None declared
Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans
Authors: Eleni-Dimitra Papanagnou, Tina Bagratuni, Efstathios Kastritis, Issidora Papassideri, Evangelos Terpos, Meletios A. Dimopoulos, Ioannis P. Trougakos
Journal: Blood (2015)
Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) &amp; European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project
Authors: Andy C Rawstron, Karl-Anton Kreuzer, Asha Soosapilla, Martin Spacek, Peter Gambell, Neil McIver-brown, Katherina Psarra, Maria Arroz, Raffaella Milani, Javier de la Serna, M. Teresa Cedena, Ozren Jaksic, Josep F. Nomdedeu, Carol Moreno, Gian Matteo Rigolin, Antonio Cuneo, Preben Johansen, Hans Erik Johnsen, Richard Rosenquist, Carsten Utoft Niemann, Wolfgang Kern, David A Westerman, Marek Trneny, Stephen P. Mulligan, Peter Hillmen, David G Oscier, Michael Hallek, Paolo Ghia, Emili Montserrat
Journal: Blood (2015)
The risk of bleeding after invasive procedures in patients with cirrhosis with severe coagulopathy
Authors: Gin‐Ho Lo
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. TO THE EDITOR: I read with interest the article by Pietri et al. regarding the use of thrombelastography (TEG)‐guided blood product use before invasive procedures in patients with cirrhosis with severe coagulopathy.1 The investigators demonstrated that TEG‐guided transfusion strategy leads to a significantly lower use of blood products, compared to transfusion guided by international normalized ratio (INR) and platelet count, and without an increase in bleeding complications. Moreover, given that postprocedure bleeding was rare, the investigators suggested that TEG thresholds should be reevaluated. This study is very helpful for managing patients with cirrhosis with severe coagulopathy requiring invasive procedures. However, a few points need further clarification. This trial enrolled only 60 patients, with 24 receiving abdominal paracentesis or thoracentesis and 10 receiving endoscopic variceal banding. These procedures actually carry a very low risk of bleeding. Banding ligation was regarded to have a bleeding risk exceeding 3%. Universal correction of INR and platelet transfusion is not recommended by international guidelines.2 A controlled study did not favor use of recombinant factor VIIa to enhance acute hemostasis.3 Multivariate analysis also did not reveal INR or platelet count as a predictive factor of early rebleeding in patients with acute variceal bleeding.4 Thus, it is difficult to ascertain the benefits on reduction of blood product transfusion in these patients based on TEG‐guided transfusion strategy over standard of care. A study with bigger sample size including more patients undergoing invasive procedures, such as hepatic resection, radiofrequency ablation, or percutaneous liver biopsy, is still required to verify the feasibility of TEG‐guided transfusion strategy.
Reduced Intensity Conditioning Allogeneic Stem cell Transplantation (RIC-alloSCT) for Elderly Acute Myeloid Leukaemia (AML) Patients Over 60 Years: A “donor” Versus “no donor” Comparison
Authors: Pierre Peterlin, Emmanuel Raffoux, Patrice Chevallier, Thierry Guillaume, Thomas Gastinne, Steven Le Gouill, Philippe Moreau, Hervé Dombret, Mohamad Mohty, Jacques Delaunay
Journal: Blood (2012)
Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia
Authors: Pedro A. Martinez, Rajasekhar NVS Suragani, Manoj Bhasin, Robert Li, Robert Scott Pearsall, Ravindra Kumar
Journal: Blood (2015)
Gastrointestinal metastasis of cardiac leiomyosarcoma
Authors: Koichiro Abe, Kazunori Seo, Minami Yagi, Yuko Sasajima, Takahiro Yagi, Tsuyoshi Inaba, Ryoji Fukushima
Journal: Endoscopy (2016)

A 78-year-old woman was admitted to our hospital with a 1-month history of fever. Two years earlier, she had undergone surgery for cardiac leiomyosarcoma in the left atrium. Pathological examination had shown complete resection of the tumor.
PWE-034 The impact of indomethacin prophylaxis on the rate of pancreatitis following endoscopic retrograde cholangiopancreatography (ercp) – a single operator experience: Abstract PWE-034 Table 1
Authors: MA Monga, Z Ahmed, M Ahmed
Journal: Gut (2015)

<h3>Introduction</h3> ERCP has become a standard therapeutic procedure for the management of biliary and pancreatic pathology. ERCP is associated with complications, especially pancreatitis (3–7%), bleeding (1%) and perforation (1%). Several recent meta-analyses indicate that rectal NSAID may reduce post-ERCP pancreatitis (PEP) by up to 50% vs placebo. <h3>Aim</h3> To assess the impact of the selective use of rectal Indomethacin prophylaxis on PEP. <h3>Method</h3> Single centre study over 3 years: Oct 2011 to Oct 2014. Analysis of 404 consecutive patients undergoing ERCP by single operator. In first 2 years Indomethacin prophylaxis was not used; in 3rd year Indomethacin 100mg per rectum was given post procedure at endoscopist’s discretion if patient considered at high risk of PEP. The endoscopy database and patient electronic records were analysed using Microsoft Excel 2010 and GraphPad Prism v6. <h3>Results</h3> <h3>Conclusion</h3> ERCP is essentially a therapeutic procedure with successful outcome in &gt;95% of cases. The pancreatitis rate has dropped from 4% to 2.32% since the introduction of indomethacin prophylaxis. Although this reduction is not statistically significant it is encouraging and in line with recently published European guidelines (ESGE June 2014) which recommend routine use of rectal NSAID for all ERCP cases. <h3>Disclosure of interest</h3> None Declared.
AB0787 Scales Elderly Patient Global Assessment Applied To Elderly Patients with Hip Fracture
Authors: A.M. Gόmez Mosquera, R.B. Melero González, T. Parajes Vázquez, C. Barbazan, M. Rodríguez Lόpez
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Analyze the potential relationship between the risk of hip fracture and the results of the scales Elderly Patient Global Rating geriatric patients. <h3>Methods</h3> Retrospective and descriptive study of a random series of 120 patients over 75 years attending emergencies in the University Hospital of Vigo in the year 2013 with a diagnosis of hip fracture. Data collected from medical records that refer to the functional, mental and social value at the time of the event are analyzed. <h3>Results</h3> Of the 120 patients analyzed in the study, 92 were women (76.6%) and 28 males (23.3%) with a mean age of 84.53 years. Considering the Elderly Patient Global Assessment in the functional area, according to the scale of disability of the Red Cross in terms of ambulation is concerned, we classified our patients in 6 degrees: grade 0 (normal walking) on 30.83% of patients; Group 1 (wanders with some difficulty) 27.5%; Grade 2 (roams using cane or similar) 17.5%; Grade 3 (roams helped at least one person) 10.83%; Grade 4 (roams helped with extreme difficulty, two people) 6.67%; and grade 5 (immobilization in bed or chair) 6.67%). Regarding the mental sphere in 75% of our patients any cognitive decline is not evidence. Only 10% of them were institutionalized at the time of the fracture. <h3>Conclusions</h3> In this series of 120 elderly patients a direct relationship between hip fracture by low-impact crash, and functional, mental and social situation is evident; being at greatest percentage of fractures, those elderly who have difficulty walking or in need of a single support, without any cognitive impairment and who live in residence. <h3>Disclosure of Interest</h3> None declared